

23

ABSTRACT

24 **Background:** Bromhexine hydrochloride has been suggested as a TMPRSS2 protease blocker
25 that precludes the penetration of SARS-CoV-2 into cells. We aimed to assess the preventive
26 potential of regular bromhexine hydrochloride intake for COVID-19 risk reduction in medical
27 staff actively involved in the evaluation and treatment of patients with confirmed or suspected
28 SARS-CoV-2 infection.

29 **Methods:** In a single-center randomized open-label study, medical staff managing patients with
30 suspected and confirmed COVID-19 were enrolled and followed up for 8 weeks. The study
31 began at the initiation of COVID-19 management in the clinic. The study was prematurely
32 terminated after the enrollment of 50 participants without a history of SARS-CoV-2 infection: 25
33 were assigned to bromhexine hydrochloride treatment (8 mg 3 times per day), and 25 were
34 controls. The composite primary endpoint was a positive nasopharyngeal swab polymerase chain
35 reaction (PCR) test for SARS-CoV-2 or signs of clinical infection within 28 days and at week 8.
36 Secondary endpoints included: time from the first contact with a person with COVID-19 to the
37 appearance of respiratory infection symptoms; the number of days before a first positive SARS-
38 CoV-2 test; the number of asymptomatic participants with a positive nasopharyngeal swab test;
39 the number of symptomatic COVID-19 cases; adverse events.

40 **Results:** The rate of the combined primary endpoint did not differ significantly between the
41 active treatment group (2/25 [8%]) and control group (7/25 [28%]); $P=0.07$. A fewer number of
42 participants developed symptomatic COVID-19 in the treatment group compared to controls
43 (0/25 vs 5/25; $P = 0.02$).

44 **Conclusion:** Although the study was underpowered, it showed that Bromhexine hydrochloride
45 prophylaxis was associated with a reduced rate of symptomatic COVID-19. The prophylactic
46 treatment was not associated with a lower combined primary endpoint rate, a positive swab PCR
47 test, or COVID-19. (ClinicalTrials.gov number, NCT04405999)

48 **Keywords:** COVID-19; SARS-CoV-2; prophylaxis; bromhexine hydrochloride; medical staff

49

INTRODUCTION

50 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of respiratory
51 disease, COVID-19 [1]. The fast SARS-CoV-2 distribution resulted in the pandemic, and the
52 number of infected subjects keeps growing [2]. Current strategies for threat reduction include
53 non-pharmacologic prophylactic measures, such as social distancing, masks and hand sanitizers,²
54 as well as antiviral and anti-cytokine agents [3, 4]. In recent trials, pharmacologic preventive
55 drugs, such as anti-malaria and antibiotic medications, have failed to prevent infection, while
56 effective prevention is urgently required [5, 6].

57 The SARS-CoV has been shown to utilize the endosomal cysteine proteases cathepsin B
58 and L (CatB/L) and the transmembrane protease serine type 2 (TMPRSS2) for binding of the S-
59 protein [7]. It has been suggested that SARS-CoV-2 penetrates alveolar cells using the same
60 mechanism [8]. The viral S-protein is attached to angiotensin-converting enzyme 2 (ACE2) of
61 pneumocytes. Then it adheres to TMPRSS2 in S1 and S2-subunits [2, 7, 8, 9, 10, 11, 12].
62 providing the possibility for the virus to enter the cell. According to this mechanistic perspective,
63 the protease TMPRSS2 can be targeted for preventing the penetration of SARS-CoV-2 into cells
64 [7, 13, 14]. Two medications that have been shown to block TMPRSS2 *in vitro*, camostat
65 mesylate and bromhexine hydrochloride; both block the ability of the protease to activate a
66 zymogen precursor of tissue plasminogen activator. Importantly, previous studies have
67 demonstrated that TMPRSS2 is blocked by a significantly lower concentration of bromhexine
68 hydrochloride than required to inactivate other proteases in cell culture [8, 13].

69 Therefore, bromhexine hydrochloride is thought to prevent the penetration of SARS-
70 CoV-2 into cells. If this would be confirmed in clinical settings, the drug might be used as a
71 prophylactic medication in subjects with a high risk of infection, including medical staff.
72 Medical staff working with COVID-19 patients are at higher risk of infection, and preventive
73 measures, including vaccination and possible pharmacologic prevention, are of paramount
74 importance.

75 We aimed to assess the preventive potential of regular bromhexine hydrochloride intake
76 for reduction of the risk of COVID-19 in medical staff actively involved in the evaluation and
77 treatment of patients with confirmed or suspected SARS-CoV-2 infection. The study was
78 conducted in the period before any vaccine against COVID-19 became available.

79 **METHODS**

80 *Study design*

81 We conducted a single-centre randomized, open-label study to evaluate 8-week prophylaxis with
82 bromhexine hydrochloride during the period of regular exposure to Covid-19 (ClinicalTrials.gov
83 number, NCT04405999). We randomly assigned health care providers in a 1:1 ratio either to
84 bromhexine hydrochloride or to a control group.

85 Study enrollment started on May 13, 2020, when the Almazov Centre began the COVID-
86 19 treatment program. After starting the enrollment, a subsequent Federal order shortened the
87 period of hospital repurposing, and the period for healthcare providers' enrollment was shortened
88 to two weeks, accordingly. Therefore, the number of enrolled subjects reached only 50 (25
89 subjects per group), which accounted for 42.4% of the initially estimated number. The admission
90 of COVID-19 patients was performed between May 13, 2020 and July 25, 2020. The follow-up
91 of the study subjects consisted was 8 weeks. The study was terminated on August 9, 2020 after
92 reaching the end of follow-up.

93 The study was approved by the Almazov National Medical Research Centre ethics
94 committee (protocol #0105-20-02C from May 12, 2020) and conducted in accordance with the
95 Declaration of Helsinki. The study protocol is provided in the English language in **Supplements**.

96 *Participants*

97 We included participants over 18 years who were employed within the emergency departments,
98 intensive care units, and clinical departments where patients with confirmed/suspected COVID-
99 19 were admitted. All participants were obliged to wear personal protective equipment (PPE) as
100 prescribed by WHO recommendations and local instructions. The PPE included respirators class

101 FFP2 or FFP3, full skin covering, and protective eyeglasses. Blood tests for SARS-CoV-2
102 antibodies were taken at baseline before randomization (serologic qualitative assessment of IgM
103 and IgG, ELISA-BEST, Vektor-Best, Novosibirsk, Russia).

104 Participants were excluded if they had symptoms of respiratory infection within the last 2
105 months or a history of COVID-19, or a positive nasopharyngeal swab polymerase chain reaction
106 (PCR) test to SARS-CoV-2 before the day of randomization, confirmed direct contact to a
107 subject positive for SARS-CoV-2 within the last 14 days or had a positive serologic test (either
108 IgM or IgG). The additional exclusion criteria were a history of gastric ulcer or other
109 contraindications to bromhexine hydrochloride, pregnancy, and any severe chronic disease.

110 *Setting*

111 Recruitment was performed via the institution's electronic communication system and via
112 personal contacts with healthcare providers. The participants provided a scanned copy of the
113 signed consent. We performed follow-up phone calls and sent e-mail surveys on days 7, 14, 21,
114 28, and at week 8. The survey asked about any follow-up testing, illness, or hospitalizations.
115 Participants who did not respond to follow-up surveys were actively contacted by text messages
116 and telephone calls.

117 *Interventions*

118 The study statisticians adjusted a software for randomization using the minimization method
119 weighing the following factors: age (categories: 18-45, 45-64, 65-74, 75-79 years), the type of
120 anticipated contacts with SARS-CoV-2 (confirmed SARS-CoV-2 infection cases within the
121 "red" zone, working closely with colleagues who had proven contacts with SARS-CoV-2
122 patients). A study coordinator sequentially assigned participants. The assignments were open to
123 investigators and participants.

124 Bromhexine hydrochloride was dispensed and shipped to participants by the study
125 coordinator. The dosing regimen for oral bromhexine hydrochloride was 8 mg 3 times per day

126 starting from the day before the first contact with COVID-19 (first day of work in a repurposed
127 department). The dosing regimen was based on previous reports [8, 15].

128 The control group was not prescribed any additional drug or placebo.

129 *Outcomes*

130 The composite primary endpoint was prespecified as a positive nasopharyngeal swab SARS-
131 CoV-2 PCR test or the presence of clinical symptoms of infection within 8 weeks after starting
132 contacts with COVID-19 subjects. COVID-19–related symptoms were assessed based on the
133 U.S. Council for State and Territorial Epidemiologists Criteria for confirmed cases (positive
134 nasopharyngeal swab PCR test), probable cases (presence of cough, shortness of breath, or
135 difficult breathing, or the presence of two or more symptoms of fever, chills, rigors, myalgia,
136 headache, sore throat, and new olfactory and taste disorders), and possible cases (the presence of
137 one or more compatible symptoms, which could include diarrhea) [16].

138 Secondary endpoints included: time from the first contact with a person with
139 suspected/confirmed COVID-19 to the appearance of respiratory infection symptoms; the
140 number of days before the first positive SARS-CoV-2 test; the number of asymptomatic
141 participants with a positive nasopharyngeal swab test; the number of mild, moderate and severe
142 COVID-19 cases; adverse events possibly related to bromhexine hydrochloride.

143 According to the study protocol, nasopharyngeal swab SARS-CoV-2 PCR tests were
144 performed every 7 days, and additional tests were performed in case of infection. The PCR test
145 was performed by qualitative analysis (DNA-technology, Moscow, Russia).

146 Outcomes were measured at 7, 14, and 28 days after study enrollment, and then at 8
147 weeks. Outcome data including PCR, COVID-19–related symptoms, adherence to the study
148 drug, and side effects, as well as not taking the study drug by the control group subjects were
149 collected through participants' reports.

150 *Sample size*

151 Initially, we estimated that 59 subjects would need to be enrolled in each group (140 subjects in
152 total, with an assumed 15% drop-out rate), when calculated using an alpha of 0.05 and 80%
153 power, assuming a primary endpoint achievement in 10% of treatment group subjects, and 30%
154 in the control arm. These numbers were derived from previous reports on the incidence of
155 COVID-19 positivity in first-line health care workers, and reports demonstrating a higher
156 proportion of COVID-19 positive Russian physicians [17-19]. However, as described in the
157 Methods section, the enrollment was ceased when 50 subjects (25 per group), were included. The
158 number of included subjects was amended by the study committee and updated on the
159 clinicaltrials.gov website after study completion on September 3, 2020.

160 *Statistical analysis*

161 The primary and secondary endpoints were assessed with the Mann-Whitney U test. Statistical
162 analysis was performed using STATISTICA software 13.0 (StatSoft, USA), according to the
163 intention-to-treat principle, with a P-value suggesting a statistically significant difference when
164 <0.05 .

165 **RESULTS**

166 *Participants*

167 Following a general notification via an institutional electronic system, one hundred and
168 fifty healthcare providers were contacted personally, and 62 positive responses were obtained.
169 Among 62 subjects who agreed to participate, 50 persons fulfilled the inclusion criteria (80.6%)
170 (**Figure 1**).

171 The demographic and clinical characteristics of the participants are presented in **Table 1**.
172 Three (6%) of the participants were hypertensive, 2 participants had hypercholesterolemia.
173 Physicians comprised 88% of the population, and nurses 12%. The median exposure time to
174 patients with confirmed/suspected COVID-19 was 7.5 hours per week.

175 Overall, 80% (40 out of 50) participants had a very high-risk exposure (contacting with
176 aerosols from intubated COVID-19 patients) and 20% (10 out of 50) - a relatively lower risk

177 exposure (contacting with suspected/confirmed COVID-19 patients). All the participants had 6-
178 hour duration shifts working with COVID-19 patients, used FFE respirators, eyeglasses, and skin
179 coverings, and had direct contact with staff outside the “red zone” without PPE.

180 Seven (14%) participants used vitamins D, C as an intention to prevent infection: 3
181 participants in the bromhexine group (3/25, 12%) and 4 participants in the control group (4/25,
182 16%; $P>0.05$). None of the participants reported any unprotected contact with COVID-19
183 patients outside the hospital.

184 There were no subject losses nor dropouts after randomization.

185 *Primary endpoint*

186 All participants completed all scheduled surveys. The primary endpoint, a positive swab test
187 and/or infection symptoms, was documented in 9/50 (18%) participants during the follow-up
188 period: in 8 - by day 28, and in 1 - by week 8 (**Tables 1 and 2**). The primary outcome rate did
189 not differ significantly between the treatment and control groups (2/25 (8%) vs 7/25 (28%),
190 respectively) ($P=0.07$). Two hospitalizations for COVID-19 pneumonia were reported in the
191 control group (2/25, 8%), and none – in the bromhexine group (0/25, $P=0.16$). No severe cases
192 with intensive care unit admission or death occurred.

193 *Secondary endpoints*

194 There was no difference between the groups in the time between the first contact with a
195 suspected/confirmed COVID-19 person and infection symptoms, or an asymptomatic positive
196 PCR test. The first positive SARS-CoV-2 PCR tests in the treatment group appeared at 2 and 3
197 weeks, and in the control group the positive tests were obtained at 2, 3, 4 weeks, and during
198 weeks 5-8 (**Table 3**). Both SARS-CoV-2 PCR positive participants in the bromhexine treatment
199 group continued the intake of the drug until two consecutive negative tests.

200 Among 9 persons with a positive PCR test, 4 were asymptomatic (2/25 – in the treatment
201 group and 2/25 – in the control group; $P>0.05$). Five participants from the control group had
202 infection symptoms: only respiratory virus infection symptoms - in 3 persons; pneumonia – in 2.

203 All participants with respiratory symptoms were positive for SARS-Cov-2 and were compatible
204 with confirmed COVID-19 per the U.S. case definition.

205 Taking together, symptomatic COVID-19 was diagnosed in the control group only: no
206 cases in the treatment group (0/25) vs 5/25 cases in the control group, $P=0.02$.

207 *Adherence and safety*

208 Missed days of bromhexine intake were reported by 4 participants, the duration of skipped
209 treatment was 1-4 days. One participant who missed two days of drug intake had a positive
210 SARS-CoV-2 PCR test (asymptomatic case). It was impossible to assess whether missed drug
211 intake and infection occurred on the same day.

212 Two participants reported adverse events possibly related to bromhexine hydrochloride
213 treatment: a short period of hot flashes at treatment initiation and transient cough. No cases of
214 treatment termination or interruption due to adverse events were reported. There were no adverse
215 events in the control group. No statistically significant difference was found in the rates of
216 adverse events between the groups.

217 No subjects in the control group reported the intake of the study medication.

218 **DISCUSSION**

219 Although generally underpowered, the present study has several important findings. The
220 primary combined endpoint, the rate of positive nasopharyngeal swab PCR tests for SARS-CoV-
221 2 or symptomatic COVID-19, was similar in both groups. However, there was a trend towards a
222 lower rate of the positive swab PCR test in the bromhexine hydrochloride treatment group.
223 Importantly, the rate of clinically significant SARS-CoV-2 infection was statistically lower in the
224 treatment group (0/25 participants) compared with the control group (5/25 participants).

225 Even though the enrollment was terminated prematurely, it should be acknowledged that
226 the rates of the primary outcome in the active treatment and control groups were equal to the
227 estimated initially (8% vs 10%, and 28% vs 30%, respectively). This suggests that the primary
228 hypothesis of a 20% reduction in the outcome might be possible with the prevention treatment.

229 Indeed, the main outcome presents an important numerical difference but without reaching
230 statistical significance, and should be interpreted with consideration of the limited sample size.

231 The risk of symptomatic and severe COVID-19 depends on age and comorbidity [20].
232 Our study population was generally younger and healthier than in the majority of COVID-19
233 studies. However, in a study of post-exposure COVID-19 prophylaxis by hydroxychloroquine,
234 the mean age and average health status of the participants were comparable [5]. Thus, for
235 prevention efficacy assessment, our group can be informative. Moreover, the fact that the safe
236 and cheap drug showed the risk reduction of symptomatic infection can be important for future
237 larger studies and practical use.

238 We used a thorough approach for detecting asymptomatic cases performing
239 nasopharyngeal swab PCR tests every week of follow-up using the approved methodology [21].

240 Two factors increase the value of our study: good adherence, which is significantly
241 higher, compared to generally published prevention studies, and the high survey response rate.
242 This can be explained by the high motivation and high awareness of the medical staff.

243 It should be mentioned that a small number of participants used additional medications,
244 including ACE2 inhibitors/ARA, or vitamin C, D. No statistical difference in the use of
245 additional pharmacological treatment was documented between the groups, and the number of
246 subjects with additional medications was very small, thus we can conclude that this aspect had
247 no impact on the study results. It is plausible that the results may be more robust with a placebo-
248 controlled group. Due to the organizational difficulties during a limited period of study
249 preparation, the provision of placebo was impossible.

250 Although all healthcare workers were instructed to wear protective masks and medical
251 gloves outside the hospital, we cannot exclude that some of the participants might have been
252 infected outside the hospital or during direct communication within the community during rest
253 and meals. However, if bromhexine hydrochloride prevention is effective, it should be effective
254 anywhere.

255 It is generally believed that the risk of infection is lower when the staff uses PPE as
256 appropriate. Thus, further reduction of clinically significant cases can be an argument for the
257 implementation of this approach into clinical practice, even before obtaining better evidence.

258 In a recently published randomized study of bromhexine hydrochloride treatment in
259 patients hospitalized with COVID-19, the authors have shown that the early administration of
260 oral bromhexine reduces the intensive care unit transfer, intubation, and mortality rate [15]. In
261 another small open-label randomized study, where 18 patients with COVID-19 were included,
262 bromhexine hydrochloride treatment has been shown associated with a trend towards the
263 improvement in chest computed tomography, the need for oxygen therapy, and discharge rate
264 within 20 days [22]. In this study, a much higher drug dosage was utilized (32 mg t.i.d.). Of note,
265 subjects were patients with confirmed mild or moderate COVID-19 disease, while in our study
266 healthy subjects were given the medication for prophylactic purposes. We have chosen a lower
267 dose of the drug (8 mg t.i.d.) according to previous research demonstrating its efficacy [8, 15]. A
268 higher Bromhexine hydrochloride dose might be associated with a higher rate of adverse events,
269 but this assumption is speculative. Although hypothesis regarding the positive effects of
270 bromhexine on viral penetration into cells in noninfected subjects differs from the background
271 presented in the two latter studies, these investigations support the assumption of positive effects
272 of the drug against SARS-CoV-2.

273 Whether the prophylactic use of bromhexine hydrochloride against SARS-CoV-2
274 infection in the general population is effective is a separate question that should be answered in
275 larger-scale randomized trials.

276 **Study limitations**

277 The major limitation of the present study is the small number of participants. The initial
278 estimation of the sample size was higher, but the enrollment was ceased earlier due to the
279 reasons declared in the Methods section. On the other hand, the sample size was sufficient to
280 demonstrate the significant difference in secondary outcomes between the groups.

281 Another limitation is the lack of sequential serologic testing, which we considered less
282 informative due to a very short study period.

283 It should be mentioned that safety and side effects data from self-reports is probably
284 limited. Theoretically, there was a risk of crossover between the groups; however, no evidence of
285 at least one crossover was found.

286 Additionally, there was no objective supervision of how and where the drugs were taken,
287 only weekly surveys were distributed and collected from participants via electronic facilities;
288 therefore, we were not able to provide any direct observation of the therapy, and the validity of
289 the intervention could not be completely verifiable.

290 In contrast to the previous study by Li T et al [22], we did not assess potential effects of
291 Bromhexine hydrochloride on COVID-19-related lung or hepatic injury, since the percentage of
292 patients with overt disease was small.

293 **CONCLUSIONS**

294 In this randomized single-centre open-label study, bromhexine hydrochloride prophylactic
295 treatment was associated with a reduction in the rate of symptomatic COVID-19 among medical
296 personnel. However, the primary combined outcome, the rate of a positive nasopharyngeal swab
297 PCR test and/or COVID-19, did not reach a statically significant difference.

298 Although generally underpowered, this study suggests that bromhexine hydrochloride
299 may offer clinical value when taken as a prophylactic treatment.

300 **FUNDING**

301 This research was supported by the Ministry of Science and Higher Education of the
302 Russian Federation (Agreement No. 075-15-2020-901).

303 **ACKNOWLEDGEMENTS**

304 The authors thank all study participants for their dedication to participate and adherence to the
305 study protocol. We thank Dr. Olesya V. Melnik, MD, PhD, for her invaluable help in serologic
306 data management. The research was performed using the core facilities of Biobank of the
307 Almazov National Medical Centre.

308 A preprint of this manuscript has previously been published [23].

309 **AUTHOR CONTRIBUTIONS**

310 Research idea: ENM, TAL, DS. Study design: ENM, TAL, AOK, EVSh. Data collection
311 and management: ENM, TAL, ADV, DSL, EYuV. Data interpretation and analysis: ENM, TAL,
312 ADV, DS, DSL, AOK, EVSh. Writing the article draft: ENM, TAL, AOK. Critical review and
313 approval of the article final version: all authors.

314 **STUDY HIGHLIGHTS**

- 315 - Bromhexine hydrochloride is a TMPRSS2 protease blocker that is thought to preclude the
316 penetration of SARS-CoV-2 into cells;
- 317 - Prophylactic treatment with bromhexine hydrochloride reduces the rate of clinical
318 infection among medical workers who manage patients with COVID-19

319

320

321

REFEREFENCES

- 322 1. Helmy YA, Fawzy M, Elasad A, Sobieh A, Kenney SP, Shehata AA. The COVID-19
323 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis,
324 treatment, and control. *J Clin Med* 2020;9(4):E1225-E1225.
- 325 2. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology,
326 transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a
327 review. *JAMA* 2020;324(8):782-793.
- 328 3. Gandhi RT, Lynch JB, Del Rio C. Mild or moderate Covid-19. *N Engl J Med*
329 2020;383(18):1757-1766.
- 330 4. Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. *N Engl J Med* 2020;
331 383(25):2451-2460.
- 332 5. Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC et al. A
333 Randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. *N*
334 *Engl J Med* 2020;383(6):517-525.
- 335 6. Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, Miller MC, Abraham GM, Obley AJ et al.
336 (2020) Update alert: should clinicians use chloroquine or hydroxychloroquine alone or in
337 combination with azithromycin for the prophylaxis or treatment of COVID-19? Living
338 practice points from the American College of Physicians. *Annals of internal medicine*
339 2020;173(2):W48-W51.
- 340 7. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S et al.
341 SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically
342 proven protease inhibitor. *Cell* 2020;181:271–280.
- 343 8. Glowacka I, Bertram S, Müller MA, Allen P, Soilleux E, Pfefferle S et al. Evidence that
344 TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for
345 membrane fusion and reduces viral control by the humoral immune response. *J Virol*
346 2011;85:4122-4134.

- 347 9. Stepanov D, Lierz P. Bromhexine hydrochloride: potential approach to prevent or treat
348 early stage COVID-19. *J Infect Dis Epidemiol* 2020;6:135.
- 349 10. Matsuyama S, Nagata N, Shirato K, Kawase M, Takeda M, Taguchi F. Efficient
350 activation of the severe acute respiratory syndrome coronavirus spike protein by the
351 transmembrane protease TMPRSS2. *J Virol* 2010;84:12658-64.
- 352 11. Shulla A, Heald-Sargent T, Subramanya G, Zhao J, Perlman S, Gallagher T. A
353 transmembrane serine protease is linked to the severe acute respiratory syndrome
354 coronavirus receptor and activates virus entry. *J Virol* 2011;85:873-82.
- 355 12. Simmons G, Gosalia DN, Rennekamp AJ, Reeves JD, Diamond SL, Bates P. Inhibitors
356 of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. *Proc Natl*
357 *Acad Sci USA* 2005;102:11876-81.
- 358 13. Lucas JM, Heinlein C, Kim T, Lucas JM, Heinlein C, Kim T et al. The androgen-
359 regulated protease TMPRSS2 activates a proteolytic cascade involving components of
360 the tumor microenvironment and promotes prostate cancer metastasis. *Cancer Discovery*
361 2014;4:1310-25.
- 362 14. Habtemariam S, Nabavi SF, Ghavami S, Cismaru CA, Berindan-Neagoe I, Nabavi SM.
363 Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent
364 against SARS-CoV-2 infection based on its action on the transmembrane serine protease
365 2. *Pharmacol Res* 2020;157:104853.
- 366 15. Ansarin K, Tolouian R, Ardalan M, Taghizadieh A, Varshochi M, Teimouri S et al.
367 Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: a
368 randomized clinical trial. *BioImpacts* 2020;10(4):209-215.
- 369 16. Council of State and Territorial Epidemiologists. Interim-20-ID-01: standardized
370 surveillance case definition and national notification for 2019 novel coronavirus disease
371 (COVID-19). Available at: [https://www.cste.org/resource/resmgr/2020ps/Interim-20-ID-](https://www.cste.org/resource/resmgr/2020ps/Interim-20-ID-01_COVID-19.pdf)
372 [01_COVID-19.pdf](https://www.cste.org/resource/resmgr/2020ps/Interim-20-ID-01_COVID-19.pdf). Accessed 05 September 2020.

- 373 17. Nguyen LH, Drew DA, Graham MS, Joshi AD, Guo CG, Ma W et al. Risk of COVID-19
374 among front-line health-care workers and the general community: a prospective cohort
375 study. *Lancet Public Health* 2020;5(9):e475-e483.
- 376 18. Dyer O. Covid-19: cases rise in Russia as health workers pay the price for PPE shortage.
377 *BMJ* 2020; m1975. Available at: <https://www.bmj.com/content/369/bmj.m1975>. Accessed
378 05 September 2020.
- 379 19. CDC COVID-19 Response Team. Characteristics of Health Care Personnel with COVID-
380 19 — United States. *Morbidity and Mortality Weekly Report*. 2020, April 17; 69(15):
381 477-481. Available at:
382 https://www.cdc.gov/mmwr/volumes/69/wr/mm6915e6.htm?deliveryName=USCDC_42
383 [5-DM25898](https://www.cdc.gov/mmwr/volumes/69/wr/mm6915e6.htm?deliveryName=USCDC_42). Accessed 05 September 2020.
- 384 20. McMichael TM, Currie DW, Clark S, Pogosjans S, Kay M, Schwartz NG et al.
385 Epidemiology of Covid-19 in a long-term care facility in King County, Washington. *N*
386 *Engl J Med* 2020;382(21):2005-2011.
- 387 21. Marty FM, Chen K, Verrill KA. How to obtain a nasopharyngeal swab specimen. *N Engl*
388 *J Med* 2020;382(22): e76.
- 389 22. Li T, Sun L, Zhang W, Zheng C, Jiang C, Chen M et al. Bromhexine hydrochloride
390 tablets for the treatment of moderate COVID-19: an open-label randomized controlled
391 pilot study. *Clin Transl Sci* 2020; 13(6):1096-1102.
- 392 23. Mikhaylov EN, Lyubimtseva TA, Vakhrushev AD et al. Bromhexine hydrochloride
393 prophylaxis of COVID-19 for medical personnel: a randomized open-label study.
394 *MedRxiv* 2021:2021.03.03.21252855.
- 395

396
397
398

TABLES

Table 1. Demographic, clinical and work characteristics of study participants

	Bromhexine treatment group	Control group	Overall	P
n	25	25	50	1.00
Age, years	41.7±6.9	39.5±8.2	40.6±7.6	0.43
Sex, n (%) of males)	11 (44%)	10 (40%)		0.78
BMI	25.1±3.9	23.9±4.1	24.6±4.0	0.76
Work within the “red zone”, n (%)	14 (56%)	11 (44%)	25 (50%)	0.41
Co-morbidity, n	2	1	3	0.82
ACEi2 inhibitors/ARA treatment, n	1	1	2	1.00
Additional Vitamin D/C pharmacological drugs, n	1	4	5	0.16
Negative serologic test for anti-SARS-CoV-2 IgM and IgG at baseline	100%	100%	100%	1.00
Time spent in the “red zone”, mean±SD; Median [IQR], hours	64.1±69.5; 40 [2; 144]	66.6±78.2; 20 [3; 160]	66.1±72.6 ; 30.0 [2; 144]	0.97
Time spent in the hospital, hours	145.1±44.5	143.2±40.6	144.2±42.2	0.66
Participants who worked in intensive care units, n	6	6	12	1.00
Participants who worked in re-purposed infectious wards or COVID-19 admission departments, n	12	14	28	0.58
Participants who worked in invasive cardiology/electrophysiology departments, n	6	4	10	0.49

399
400
401
402
403

n, number of participants; BMI, body mass index; ACEi2, angiotensin 2 converting enzyme inhibitors; ARA, angiotensine receptor antagonists; SD, standard deviation; IQR, interquartile range; PCR, polymerase chain reaction

404 **Table 2. Study outcomes: positive PCR tests and COVID-19**

405

	Bromhexine treatment group	Control group	Overall	P
n	25	25	50	1.00
Primary outcome (Positive PCR test or COVID-19)	2	7	9	0.07
Positive SARS-CoV-2 PCR test, n	2	7	9	0.07
Asymptomatic	2	2	4	1.00
Symptomatic	0	5	5	0.02
COVID-19 moderate, n	0	3	3	0.08
COVID-19 severe with hospitalization, n	0	2	2	0.16
Drug non-adherence				
Missed doses of bromhexine, n	4	-	-	-
Number of missed bromhexine doses, Median [IQR]	6 [5.25; 7.5]	-	-	-
Adverse events, n	2	0	2	0.16

406

407 n, number of participants; IQR, interquartile range; PCR, polymerase chain reaction

408

409 **Table 3. Timeline of positive SARS-CoV-2 tests in both groups.**

		Days 1-7	Days 8-14	Days 15-21	Days 22-28	Weeks 5-8	Total
Number of participants with a positive PCR test	Treatment group	0/25	1/25	1/24	0/23	0/23	2/25
	Control group	0/25	2/25	3/23	1/20	1/19	7/25
Number of participants with clinical symptoms of respiratory infection	Treatment group	0/25	0/25	0/25	0/25	0/25	0/25
	Control group	0/25	0/25	2/25	3/23	0/20	5/25

410


411 Numbers of subjects with an outcome are divided by the number of subjects at risk. Three
 412 patients developed clinical symptoms after positive PCR test in the previous period (days 8-14
 413 and days 15-21). P>0.05 for each period of follow-up.

414

415

416

FIGURES



417

418

419 **Figure 1.** Study flowchart.

420

421 **SUPPLEMENT FILE.** This file contains study protocol translated to English.